TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01011010

Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin hydrochloride
Description: TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: mitomycin C
Description: TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: sorafenib tosylate
Description: Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Description: Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Description: Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
Study: NCT00627705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar pill
Description: Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous).
Study: NCT00522249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Alfa Interferon
Description: Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
Study: NCT03590301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FUNPALs Playgroup
Description: Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Toddler Parent Group
Description: The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
Study: NCT02693990

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Description: Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Description: Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Description: Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
Study: NCT04590703

Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.

Intervention type: PROCEDURE
Intervention: Vehicle sheet
Description: Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
Study: NCT02269293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Study: NCT04105023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Administered orally once every 12 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once every 12 hours
Study: NCT02446561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRXXX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR1XXX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR2XXX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR3XXX
Study: NCT02594891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic retrograde biliary drainage
Description: A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: endoscopic nasobiliary drainage
Description: A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
Study: NCT02493127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard PCS
Description: Subject completes the standard version of the PCS Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grip Strength
Description: Research Assistant takes Grip Strength Measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grip Strength
Description: Research Assistant takes Grip Strength Measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positively Adjusted PCS
Description: Subject completes the positively-adjusted version of the PCS Questionnaire
Study: NCT02978365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic Strength Measurement
Description: Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
Study: NCT03372226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help program
Description: The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
Study: NCT04915963

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Vitamin D supplementation
Description: Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
Study: NCT01815411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom extract
Description: The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
Study: NCT03357432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gelatin, collagen, gummy dose
Description: The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a \>24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
Study: NCT04915963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
Study: NCT01660906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: tablets, oral, 100 mg, Once daily, Up to12 months on study,
Study: NCT01651429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
Study: NCT04380571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
Study: NCT02916160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)
Description: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
Study: NCT00776633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
Study: NCT03483636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: 0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: 0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated oral tablet
Study: NCT02142049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study: NCT00776633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 6 months triple therapy with aspirin, clopidogrel and oral anticoagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral anticoagulation
Study: NCT02142049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study: NCT00776633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anticoagulation
Study: NCT02065791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg over-encapsulated tablet orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once daily
Study: NCT01951547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Description: Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
Study: NCT02142049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study: NCT00497302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBT
Description: Contingency management and behavioral counseling including motivational interviewing
Study: NCT01055444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heated lidocaine and tetracaine topical patch
Description: Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
Study: NCT00497302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: receives usual comprehensive care at Center for Addiction and Pregnancy
Study: NCT02037347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Study: NCT01765634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-mesenchymal stem cells
Description: Other second line drugs are taken.
Study: NCT01870271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmentally adapted cognitive processing therapy
Study: NCT02096900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolpidem
Description: Zolpidem will be given one time at 0.25 mg/kg pre-operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT01579708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program SI! educational intervention
Description: School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
Study: NCT03216876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic acid
Description: Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic acid
Description: Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic acid
Description: Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
Study: NCT03829904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGH-BPH1
Description: A scientific Chinese granule powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Corn starch pill manufactured to mimic VGH-BPH1)
Description: Corn starch pill manufactured to mimic VGH-BPH1
Study: NCT02832323

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Reticera
Description: A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
Study: NCT01432119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: 100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: 100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Break-Through Scan
Description: Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Break-Through Scan
Description: Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.